What type of study is this?

September 10, 2025Cancer Research

Abstract LT01: Identifying Optimal Tumour-specific Promoters for CRISPR/Cas9 Engineering of Armoured CAR T Cells with Enhanced Safety and Efficacy

View Full Paper

Ask AI

Bookmark

Authors

Genome-wide analysis identifies tumour-specific promoters for CRISPR/Cas9 engineering, suggesting improved efficacy and safety in CAR-T cells.

CRISPR/Cas9-mediated knock-in of tumour-specific promoters enhanced CAR-T cell safety and efficacy in mouse models.
The study identified NR4A2 and RGS16 as effective promoters for restricted expression of IL-12 and IL-2, minimizing adverse effects.
Endogenous gene regulatory elements were leveraged, demonstrating improved CAR-T cell functionality and activation of anti-tumour immunity.
This approach may lead to more effective clinical applications, as it is applicable to patient-derived CAR-T cells.

Yap et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Genome-wide analysis identifies tumour-specific promoters for CRISPR/Cas9 engineering, suggesting improved efficacy and safety in CAR-T cells.